Plus, news about Vicore:
Scholar Rock seeks $275M in stock sale: After announcing the success of a pivotal clinical trial for its muscle-targeted spinal muscular atrophy treatment, Scholar Rock’s shares $SRRK skyrocketed over 300% on Monday. The biotech is now seeking $275 million via a public offering. It plans to put the money towards funding the commercialization of its SMA therapy apitegromab, among other uses. — Lei Lei Wu
Vincerx reprioritizes its pipeline: The Palo Alto, CA-based biotech said it will partner off its advanced solid tumor candidate, VIP236, and instead focus resources on continued development of VIP943 for acute myeloid leukemia. Vincerx is also looking for a partner for its diffuse large B cell lymphoma asset, called enitociclib. The company has a cash runway through early next year. Its stock $VINC was down about 19% on Tuesday morning. — Ayisha Sharma
Vicore raises SEK 100M in share sale: The biotech issued more than 11 million new shares for SEK 9 apiece, securing the equivalent of $9.6 million. The proceeds are expected to help the drugmaker fund an expanded Phase 2b test of its idiopathic pulmonary fibrosis drug candidate, buloxibutid, and get ready for registrational development. — Ayisha Sharma